Immunome CMO exercises options, sells 55,000 shares

Rhea-AI Filing Summary

Robert Lechleider, Chief Medical Officer of Immunome, exercised stock options for 55,000 shares of common stock at $8.73 per share on July 2, 2026, then sold 55,000 shares in three tranches at weighted average prices of $21.95, $22.76 and $23.44 per share under a Rule 10b5-1 trading plan adopted on March 26, 2026. Following these transactions, he directly holds 15,805 shares of common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 55,000 shares ($764K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Lechleider Robert

Role Chief Medical Officer

Sold 55,000 shs ($1.24M)

Approx. gross sale proceeds $1.24M

Approx. exercise cost $480K

Approx. pre-tax spread $764K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (right to buy)	55,000	$0.00	$0.00
Exercise	Common Stock	55,000	$8.73	$480K
Sale	Common Stock	22,714	$21.95	$499K
Sale	Common Stock	16,214	$22.76	$369K
Sale	Common Stock	16,072	$23.44	$377K

Holdings After Transaction: Employee Stock Option (right to buy) — 290,000 contracts (Direct); Common Stock — 15,805 shares (Direct)

Footnotes (5)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.
2. F2. The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
3. F3. The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
4. F4. The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
5. F5. 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.

Key Figures

Options exercised: 55,000 shares Option exercise price: $8.73 per share Shares sold: 55,000 shares +5 more

8 metrics

Options exercised 55,000 shares Employee Stock Option exercised on 2026-07-02

Option exercise price $8.73 per share Exercise price of Employee Stock Option

Shares sold 55,000 shares Aggregate common shares sold on 2026-07-02

Sale price tranche 1 $21.95 per share Weighted average price for one sale tranche

Sale price tranche 2 $22.76 per share Weighted average price for one sale tranche

Sale price tranche 3 $23.44 per share Weighted average price for one sale tranche

Post-transaction holdings 15,805 shares Direct common stock held after transactions

Option expiration date 2033-10-26 Expiration date of the Employee Stock Option

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Employee Stock Option (right to buy), vesting

4 terms

Rule 10b5-1 trading plan financial

"The sales were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The weighted average sale price for the transaction report was $21.95"

Employee Stock Option (right to buy) financial

"Security title listed as Employee Stock Option (right to buy)"

vesting financial

"25% of the shares subject to the option vested on October 16, 2024"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Immunome (IMNM) report for its CMO on July 2, 2026?

Immunome’s CMO Robert Lechleider exercised options for 55,000 shares at $8.73 per share and sold 55,000 common shares on July 2, 2026. The sequence was an option exercise into stock followed by three same-day sale transactions.

How many shares did Immunome’s (IMNM) CMO sell and at what prices?

Robert Lechleider sold a total of 55,000 Immunome common shares in three tranches. The reported weighted average prices were $21.95, $22.76 and $23.44 per share, each within specified intraday price ranges described in the transaction footnotes.

How many Immunome (IMNM) shares does Robert Lechleider own after these transactions?

Following the July 2, 2026 transactions, Robert Lechleider directly holds 15,805 Immunome common shares. This post-transaction holding reflects the reported option exercise, the subsequent sale of 55,000 shares, and the remaining directly owned shares disclosed in the position table.

What stock options did Immunome’s (IMNM) CMO exercise and how do they vest?

He exercised an Employee Stock Option for 55,000 shares at $8.73 per share, expiring on October 26, 2033. Footnotes state 25% of the option vested on October 16, 2024, with the remaining shares vesting monthly over three years.

Were the Immunome (IMNM) insider sales made under a Rule 10b5-1 plan?

Yes. The filing notes that the sales were effected under a Rule 10b5-1 trading plan adopted by Robert Lechleider on March 26, 2026. Such plans pre-arrange trades, which can reduce the informational value of the exact sale timing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 05:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lechleider Robert

(Last) (First) (Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		M		55,000	A	$8.73	70,805	D
Common Stock	07/02/2026		S(1)		22,714	D	$21.95(2)	48,091	D
Common Stock	07/02/2026		S(1)		16,214	D	$22.76(3)	31,877	D
Common Stock	07/02/2026		S(1)		16,072	D	$23.44(4)	15,805	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$8.73	07/02/2026		M			55,000	(5)	10/26/2033	Common Stock	55,000	$0	290,000	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 26, 2026.

2. The weighted average sale price for the transaction report was $21.95, and the range of prices were between $21.26 and $22.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The weighted average sale price for the transaction report was $22.76, and the range of prices were between $22.26 and $23.25, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The weighted average sale price for the transaction report was $23.44, and the range of prices were between $23.26 and $23.67, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

5. 25% of the shares subject to the option vested on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.

	/s/ Sandra G. Stoneman, Attorney-in-Fact	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)